Clinical and microbiologic outcomes in trauma patients treated for Stenotrophomonas maltophilia ventilator-associated pneumonia

Pharmacotherapy

Volumn 31, Issue 4, 2011, Pages 338-345

  Czosnowski, Quinn A ^a   Wood, G Christopher ^b   Magnotti, Louis J ^b   Croce, Martin A ^b   Swanson, Joseph M ^b   Boucher, Bradley A ^b   Fabian, Timothy C ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Stenotrophomonas maltophilia; TMP SMX; Trimethoprim sulfamethoxazole; VAP; Ventilator associated pneumonia; Xanthomonas maltophilia

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTETAN; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; SULTAMICILLIN; TIMENTIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; DATA INTERPRETATION, STATISTICAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MEDICAL RECORDS; PNEUMONIA, VENTILATOR-ASSOCIATED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WOUNDS AND INJURIES;

EID: 79953710010     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.4.338     Document Type: Article

References (36)

1. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 2007;26(1):13-20.
2. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001;32(suppl 2):S104-13.
3. Schaumann R, Stein K, Eckhardt C, Ackermann G, Rodloff AC. Infections caused by Stenotrophomonas maltophilia - a prospective study. Infection 2001;29(4):205-8. (Pubitemid 32762207)
4. Nseir S, Di Pompeo C, Brisson H, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome [online exclusive article]. Crit Care 2006;10(5):R143. Available from http://ccforum.com/content/10/5/R143.
5. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH. The impact of multidrug resistance on the outcomes of critically ill patients with gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis 2007;58(1):99-104. (Pubitemid 46694269)
6. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108(6):1655-62.
7. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother 2001;48(1):152-4.
8. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002;35(3):228-35. (Pubitemid 34800268)
9. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 1997;18(5):316-21. (Pubitemid 127470482)
10. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.
11. Croce MA, Fabian TC, Mueller EW, et al. The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma 2004;56(5):931-4, discussion 934-6.
12. Wood GC, Mueller EW, Croce MA, Boucher BA, Hanes SD, Fabian TC. Evaluation of a clinical pathway for ventilator-associated pneumonia: changes in bacterial flora and the adequacy of empiric antibiotics over a three-year period. Surg Infect (Larchmt) 2005;6(2):203-13. (Pubitemid 41388155)
13. Mueller EW, Croce MA, Boucher BA, et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma 2007;63(6):1329-37, discussion 1337.
14. Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009;29(9):1054-60.
15. Hedrick TL, Smith RL, McElearney ST, et al. Differences in early- and late-onset ventilator-associated pneumonia between surgical and trauma patients in a combined surgical or trauma intensive care unit. J Trauma 2008;64(3):714-20. (Pubitemid 351366897)
16. Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator associated pneumonia caused by non-fermentative gram-negative bacilli. Surg Infect (Larchmt) 2007;8(6):589-97.
17. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34(11):1425-30. (Pubitemid 34553700)
18. Magnotti LJ, Schroeppel TJ, Clement LP, et al. Efficacy of monotherapy in the treatment of Pseudomonas ventilator-associated pneumonia in patients with trauma. J Trauma 2009;66(4):1052-8, discussion 1058-9.
19. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008;36(1):108-17.
20. Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ, Bernstein JM. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: a study of 143 patients. Heart Lung 1999;28(2):134-41. (Pubitemid 29141035)
21. Maningo E, Watanakunakorn C. Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units. J Infect 1995;31(2):89-92.
22. Morrison AJ Jr, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986;24(1):52-5. (Pubitemid 16090234)
23. Tseng CC, Fang WF, Huang KT, et al. Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia. Infect Control Hosp Epidemiol 2009;30(12):1193-202.
24. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115(2):462-74. (Pubitemid 29083057)
25. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-55. (Pubitemid 30485502)
26. Mueller EW, Hanes SD, Croce MA, Wood GC, Boucher BA, Fabian TC. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma 2005;58(1):94-101.
27. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008;62(5):889-94.
28. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep Recomm Rep 2009;58(RR-4):1-207.
29. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.
30. Stevens RC, Laizure SC, Sanders PL, Stein DS. Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob Agents Chemother 1993;37(3):448-52. (Pubitemid 23072587)
31. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials [online exclusive article]. BMJ 2004;328(7441):668. Available from http://www.bmj.com/content/328/7441/668.full. (Erratum in BMJ 2004;328(7444):884.)
32. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41(2):149-58. (Pubitemid 40962494)
33. Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995;39(10):2220-3.
34. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004;48(1):168-71. (Pubitemid 38040193)
35. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996;124(3):316-20.
36. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993;119(4):291-5. (Pubitemid 23319886)